19th May 2022 | Pharma Updates
Sun Pharma introduce a new oral lipid-lowering drug under the Brillo brand
Sun Pharmaceutical Industries intends to launch Bempedoic Acid, a first-in-class lipidlowering oral drug that aids in the reduction of low-density lipoprotein cholesterol, in India and Brillo will be the drug’s brand name when it is released.
Docflix, an OTT platform for doctors launched by Mankind Pharma
Mankind Pharma has entered the over-the-top (OTT) market with the launch of Docflix which appears to be a play on streaming giant Netflix, will have a wide range of scientific content tailored to various practise needs of doctors in the country.
The deal between Serum Institute Life Sciences and Biocon Biologics approved by CCI
The SI Life Sciences, Covidshield Technologies, and Biocon Biologics merger has been approved by the Competition Commission of India. Serum Institute Life Sciences Pvt Ltd will own approximately 15% of Biocon Biologics Ltd once the transaction is completed.
Tirzepatide Receives FDA Approval for Type 2 Diabetes
The “Twincretin” era in the treatment of type 2 diabetes has begun, with the FDA’s approval of tirzepatide for this indication on May 13, making it the first approved agent that works as a dual agonist for the two major human incretins.
Gujarat receives USD 350 billion from the World Bank to improve health-care services
World Bank delegation met with Gujarat Health Minister Hrishikesh Patel to discuss the implementation of the Systems Reform Endeavours for Transformed Health Achievement in Gujarat (SRESTHA-G) project.
Aurobindo Pharma benefits as the USFDA completes its inspection with no deficiencies
Aurobindo Pharma ascended 3.53 percent to Rs 554.95 after clearing five USFDA observations on Wednesday. The pre approval inspection took place from February 8th to February 15th, 2022.
AffyXell and GenScript ProBio expanding their manufacturing partnership
AffyXell, a joint venture with South Korean drug maker Daewoong Pharmaceutical, has expanded its partnership with GenScript ProBio, a biopharmaceutical manufacturer, as per Avacta Group, a clinical-stage oncology drug company developing cancer therapies.